

# VACCINE ADVISORY

From the Texas Department of State Health Services Immunization Branch

---

*The goal of the Vaccine Advisory is to disseminate, in a timely manner, practical information related to vaccines, vaccine-preventable diseases, and the vaccine programs managed by the Immunization Branch. The Immunization Branch welcomes readers' input to improve the contents of this document.*

**The Vaccine Advisory is now available online! To view past issues, go to:**  
[www.dshs.state.tx.us/immunize/vacadvise/](http://www.dshs.state.tx.us/immunize/vacadvise/)

**July 6, 2009**

## **Advisory No. 12. Kinrix - The New Combined IPV and DTaP Vaccine**

On June 26, 2008, the Advisory Committee on Immunization Practices (ACIP) voted to add the newly licensed combination DTaP-IPV (Kinrix) vaccine as a routinely recommended vaccine. Kinrix, manufactured by GlaxoSmithKline, is designed to protect children 4-6 years of age against diphtheria, tetanus, pertussis, and polio. This advisory summarizes the indications for Kinrix and provides guidance from the ACIP for its use. The full ACIP recommendations may be found at

[http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5739a4.htm?s\\_cid=mm5739a4\\_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5739a4.htm?s_cid=mm5739a4_e).

### **This advisory contains:**

1. Background information
2. Summary of ACIP's recommendations for Kinrix vaccine
3. Texas Vaccines for Children program
4. ImmTrac
5. Texas school and child-care facilities requirements for Kinrix vaccine
6. Epidemiology and surveillance
7. Reporting vaccine adverse events
8. Resources

### **1) Background**

On June 24, 2008, the Food and Drug Administration (FDA) licensed a combined diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP) and inactivated poliovirus (IPV) vaccine, Kinrix, manufactured by GlaxoSmithKline. Kinrix is licensed for use as a booster dose in children aged 4-6 years, following a series of Infanrix and/or Pediarix.

On June 26, 2008, the ACIP endorsed the licensed indications and offered the following guidance, summarized below, for use of DTaP-IPV (Kinrix) vaccine.

## 2) Summary of ACIP recommendations

Indications and guidance for use of Kinrix vaccine follows:

- Kinrix (DTaP-IPV) is indicated for use as the fifth dose of DTaP and fourth dose of IPV in children aged 4-6 years who received DTaP (Infanrix) and/or DTaP-Hepatitis B-IPV (Pediarix) as the first 3 doses and DTaP (Infanrix) as the fourth dose.
- Kinrix should not be administered to children aged <4 years or ≥7 years; however, if DTaP-IPV (Kinrix) is inadvertently administered for an earlier dose of the DTaP and/or IPV series, the dose should be counted as valid and does not need to be repeated provided minimum interval requirements have been met.
- Data are limited on the safety and immunogenicity of interchanging DTaP vaccines from different manufacturers
- ACIP recommends that, whenever feasible, the same manufacturer's DTaP vaccines should be used for each dose in the series; however vaccination should not be deferred because the type of DTaP previously administered is unavailable or unknown.

## 3) Texas Vaccines for Children Program

Beginning January 1, 2009, Kinrix became available through the Texas Vaccines for Children (TVFC) Program, and is approved for the booster dose at age 4-6 years.

Kinrix vaccine may be ordered using the TVFC Biological Order Form (C-68). The number of doses requested should be consistent with the 4-6 year old patient population as it relates to ordering frequency. Inventory and usage should be submitted monthly along with other vaccines using the Monthly Biological Report (C-33). A revised C-33 that includes Kinrix can be found at <http://www.dshs.state.tx.us/immunize/docs/C-33.pdf>. Providers should begin using this new version immediately. The CPT code is 90696.

To access complete prescribing information for Kinrix vaccine, please reference the package insert or <http://www.fda.gov/cber/label/kinrixLB.pdf>. For other questions, contact your Health Service Region, Local Health Department, or TVFC consultant.

## 4) ImmTrac

ImmTrac users can report the DTaP and IPV (Diphtheria, Tetanus, Acellular Pertussis/inactive Polio) vaccine, Kinrix, using the ImmTrac code “**DTaP/IPV**”. Although ImmTrac can record Kinrix vaccine doses administered, and doses will be reflected on the client immunization history, the ImmTrac immunization scheduler will not generate recommendations for Kinrix vaccine at this time. Providers should consult ACIP recommendations to determine when the Kinrix vaccine should be administered.

For more information about ImmTrac, please visit [www.ImmTrac.com](http://www.ImmTrac.com).

## 5) Texas school and child-care facilities requirements for Kinrix vaccine

Kinrix (DTaP-IPV) vaccine can be given to children 4-6 years of age as the fifth dose in the DTaP series and the fourth dose in the IPV series, following a series of Infanrix and/or Pediarix.

The Immunization requirements for school and child-care facilities remain the same and can be viewed at <http://www.dshs.state.tx.us/immunize/school/default.shtm#infoforschoolchildcare>.

## 6) Epidemiology and surveillance

Pertussis, or whooping cough, is an acute, highly infectious, toxin-mediated disease caused by the bacterium *Bordetella pertussis*. Disease in adolescents and adults may be milder and go undetected in these individuals. However, they are still capable of transmitting the disease to other susceptible individuals, especially those most vulnerable, infants. Pertussis is the second most commonly reported vaccine-preventable disease in Texas. In 2008, approximately 1,900 cases of pertussis and 4 infant deaths due to pertussis occurred in Texas. This is an increase from the previous year (1,051 cases, 0 deaths). Pertussis typically peaks in three year cycles. The majority of cases occur among infants younger than 1 year of age and adults.

Pertussis is a reportable condition in Texas. All suspected cases are to be reported to the health department within 1 working day. To report pertussis, please call (800) 705-8868.

## 7) Reporting adverse vaccine events

Clinically significant adverse events following vaccination should be reported to the Vaccine Adverse Event Reporting System (VAERS).

Adverse events from privately purchased vaccine may be reported directly to VAERS at <http://vaers.hhs.gov/>. Secure web-based reporting is available on the VAERS website. Contact 800-VAC-RXNS for forms and information.

In Texas, reports of events following vaccination at public health clinics or with vaccine provided through public funding such as the Texas Vaccines for Children (TVFC) program should be reported through the Texas Department of State Health Services, Immunization Branch (MC 1946), P.O. Box 149347, Austin, TX 78714-9347. The pre-addressed and postage-paid VAERS form with this address can be obtained by calling the Immunization Branch. A copy of the form is also available in the TVFC toolkit. To request a VAERS form or additional information, call the VAERS contact in your area:

- **In Texas:** (800) 252-9152
- **For Bexar County:** (210) 207-2087
- **For City of Houston:** (713) 558-3518

## 8) Additional resources

- **For providers (Vaccine):**

- Kinrix package insert (pdf file): [http://us.gsk.com/products/assets/us\\_kinrix.pdf](http://us.gsk.com/products/assets/us_kinrix.pdf)
- DTaP Vaccine Information Statement: <http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-dtap.pdf>
- Polio Vaccine Information Statement: <http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-IPV.pdf>

- **For public (Diseases):**

- Diphtheria: <http://www.cdc.gov/vaccines/vpd-vac/diphtheria/default.htm>
- Pertussis: <http://www.cdc.gov/vaccines/vpd-vac/pertussis/default.htm>
- Tetanus: <http://www.cdc.gov/vaccines/vpd-vac/tetanus/default.htm>
- Polio: <http://www.cdc.gov/vaccines/vpd-vac/polio/default.htm>

*We hope you generously forward this advisory to others who may benefit from this information.*

---

Texas Department of State Health Services Immunization Branch (MC 1946)  
P.O. Box 149347, Austin, Texas, 78714-9347. (512) 458-7284 or (800) 252-9152  
[www.ImmunizeTexas.com](http://www.ImmunizeTexas.com)

